Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod in Refractory Lupus Nephritis
NCT03054545Unknown
- Sponsor
- Renji Hospital
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of iguratimod in lupus nephritis (LN), sponsored by Renji Hospital. Primary endpoint: Renal remission rate at 52 weeks. Status: unknown.
02
Drugs
iguratimod
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT03054545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054545.